CRISPR/Cas9基因编辑系统在结直肠癌中的应用进展  

Application of CRISPR/Cas9 Gene Editing System in Colorectal Cancer

作　　者：沈伟男 谢阳阳[2] 范晓翔[3] 戴晓宇 余永明[2] 赵坚培[2] 于骅[4] 周海萍[2] SHEN Weinan;XIE Yangyang;FAN Xiaoxiang;DAI Xiaoyu;YU Yongming;ZHAO Jianpei;YU Hua;ZHOU Haiping(Medicine School of Ningbo University,Ningbo 315211,China;Department of Anus&Intestine Surgery,Ningbo NO.2 Hospital,Ningbo 315010,China;Department of Ultrasound Intervention,Ningbo NO.2 Hospital,Ningbo 315010,China;Department of Nutrition,Ningbo NO.2 Hospital,Ningbo 315010,China)

机构地区：[1]宁波大学医学院,浙江宁波315211 [2]宁波市第二医院肛肠外科,浙江宁波315010 [3]宁波市第二医院超声介入科,浙江宁波315010 [4]宁波市第二医院营养科,浙江宁波315010

出　　处：《医学综述》2018年第24期4852-4857,共6页Medical Recapitulate

基　　金：浙江省医药卫生科技计划(2018KY690;2018KY699;2017KY593;2017KY594);宁波市自然基金(2017A610145;2017A610158;2016A610135);宁波市第二医院"华美研究基金"(2017HMKY09)

摘　　要：结直肠癌(CRC)是常见的恶性肿瘤,在我国发病率有上升趋势。近年来,从基因水平研究结肠癌的发生、发展及预后,寻找更有效的治疗方法已成为热点。成簇规律间隔的短回文重复序列/CRISPR相关蛋白酶9(CRISPR/Cas9)已成为编辑生物体基因的一项有力工具。它首次在细菌和古生菌内作为适应性免疫系统的一部分被发现,CRISPR/Cas9已广泛用于编辑基因组以及激活或抑制基因的表达。因此,CRISPR/Cas9通过提供有效的技术来分析肿瘤发生机制,鉴定靶向基因药物,有望加快癌症研究。Colorectal cancer(CRC)is a common malignant tumor,the incidence of which is in uptrend in China.In recent years,the research on the genesis,development and prognosis of CRC on genetic level to find more effective treatment has become a hotspot.Clustered regulatory interspaced short palindromic repeats/CRISPR-associated protein 9(CRISPR/Cas9)has become a powerful tool for editing the genome of many organisms.It was first discovered in bacteria and archaea as part of an adaptive immune system,CRISPR/Cas9 has been found a widespread use to edit genomes and activate or repress the expression of genes.As such,CRISPR/Cas9 is promising to accelerate cancer research by providing an efficient technology to dissect mechanisms of tumorigenesis,and identify targets for drug development.

关 键 词：结直肠癌 成簇规律间隔的短回文重复序列/CRISPR相关蛋白酶9 基因编辑 

分 类 号：R735.35[医药卫生—肿瘤] Q78[医药卫生—临床医学]